Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights

References

• Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67:792–810. doi:10.1053/j.ajkd.2015.07.037
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76:149–168. doi:10.1038/ki.2009.128
   PubMed Web of Science ®Google Scholar
• Cornec-le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919–935. doi:10.1016/S0140-6736(18)32782-X
   PubMed Web of Science ®Google Scholar
• Chapman AB, Devuyst O, Eckardt K-U, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2015;88:17–27. doi:10.1038/ki.2015.59
   PubMed Web of Science ®Google Scholar
• Geng L, Segal Y, Peissel B, et al. Identification and localization of polycystin, the PKD1 gene product. J Clin Invest. 1996;98:2674–2682. doi:10.1172/JCI119090
   PubMed Web of Science ®Google Scholar
• Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, et al. Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci U S A. 1997;94:6397–6402. doi:10.1073/pnas.94.12.6397
   PubMed Web of Science ®Google Scholar
• Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest. 1999;104:1459–1468. doi:10.1172/JCI5111
   PubMed Web of Science ®Google Scholar
• Malekshahabi T, Khoshdel Rad N, Serra AL, Moghadasali R. Autosomal dominant polycystic kidney disease: disrupted pathways and potential therapeutic interventions. J Cell Physiol. 2019;234:12451–12470. doi:10.1002/jcp.28094
   PubMed Web of Science ®Google Scholar
• Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108:2462–2467. doi:10.1073/pnas.1011498108
   PubMed Web of Science ®Google Scholar
• Su Q, Hu F, Ge X, et al. Structure of the human PKD1-PKD2 complex. Science. 2018;361:eaat9819. doi:10.1126/science.aat9819
   PubMed Web of Science ®Google Scholar
• Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124:2315–2324. doi:10.1172/JCI72272
   PubMed Web of Science ®Google Scholar
• Xu GM, Sikaneta T, Sullivan BM, et al. Polycystin-1 interacts with intermediate filaments. J Biol Chem. 2001;276:46544–46552. doi:10.1074/jbc.M107828200
   PubMed Web of Science ®Google Scholar
• Hildebrandt F, Benzing T, Katsanis N, Schwartz RS. Ciliopathies. N Engl J Med. 2011;364:1533–1543. doi:10.1056/NEJMra1010172
   PubMed Web of Science ®Google Scholar
• Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003;33:129–137. doi:10.1038/ng1076
   PubMed Web of Science ®Google Scholar
• Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol. 2001;184:71–79. doi:10.1007/s00232-001-0075-4
   PubMed Web of Science ®Google Scholar
• Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta. 2011;1812:1291–1300. doi:10.1016/j.bbadis.2010.11.005
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25:18–32. doi:10.1681/ASN.2013040398
   PubMed Web of Science ®Google Scholar
• Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci. 1997;22:217–224. doi:10.1016/s0968-0004(97)01050-5
   PubMed Web of Science ®Google Scholar
• Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol. 2000;279:F400–F416. doi:10.1152/ajprenal.2000.279.3.F400
   PubMed Web of Science ®Google Scholar
• Wang X, Ward CJ, Harris PC, Torres VE. Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int. 2010;77:129–140. doi:10.1038/ki.2009.438
   PubMed Web of Science ®Google Scholar
• Hanaoka K, Devuyst O, Schwiebert EM, Wilson PD, Guggino WB. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol. 1996;270:C389–C399. doi:10.1152/ajpcell.1996.270.1.C389
   PubMed Web of Science ®Google Scholar
• Wallace DP, Grantham JJ, Sullivan LP. Chloride and fluid secretion by cultured human polycystic kidney cells. Kidney Int. 1996;50:1327–1336. doi:10.1038/ki.1996.445
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000;57:1460–1471. doi:10.1046/j.1523-1755.2000.00991.x
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med. 2007;261:17–31. doi:10.1111/j.1365-2796.2006.01743.x
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Wallace DP, Magenheimer BS, et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem. 2004;279:40419–40430. doi:10.1074/jbc.M405079200
   PubMed Web of Science ®Google Scholar
• Welling PA, Ho K. A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am J Physiol Renal Physiol. 2009;297:F849–F863. doi:10.1152/ajprenal.00181.2009
   PubMed Web of Science ®Google Scholar
• Dere R, Wilson PD, Sandford RN, Walker CL, Blagosklonny MV. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One. 2010;5:e9239. doi:10.1371/journal.pone.0009239
   PubMed Web of Science ®Google Scholar
• Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–590. doi:10.1016/s0092-8674(03)00929-2
   PubMed Web of Science ®Google Scholar
• Olsan EE, Mukherjee S, Wulkersdorfer B, et al. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A. 2011;108:18067–18072. doi:10.1073/pnas.1111966108
   PubMed Web of Science ®Google Scholar
• Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens. 2009;18:99–106. doi:10.1097/MNH.0b013e3283262ab0
   PubMed Web of Science ®Google Scholar
• Bell PE, Hossack KF, Gabow PA, et al. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1988;34:683–690. doi:10.1038/ki.1988.233
   PubMed Web of Science ®Google Scholar
• Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323:1091–1096. doi:10.1056/NEJM199010183231602
   PubMed Web of Science ®Google Scholar
• Ecder T, Edelstein CL, Chapman AB, et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999;14:1113–1116. doi:10.1093/ndt/14.5.1113
   PubMed Web of Science ®Google Scholar
• Torres VE, Abebe KZ, Schrier RW, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017;91:493–500. doi:10.1016/j.kint.2016.10.018
   PubMed Web of Science ®Google Scholar
• Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160–172. doi:10.1681/ASN.2013101138
   PubMed Web of Science ®Google Scholar
• Bae KT, Sun H, Lee JG, et al. Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol. 2014;39:210–217. doi:10.1159/000358604
   PubMed Web of Science ®Google Scholar
• Torres VE. Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2019;34:30–34. doi:10.1093/ndt/gfy297
   PubMed Web of Science ®Google Scholar
• Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363–364. doi:10.1038/nm1004
   PubMed Web of Science ®Google Scholar
• Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102–108. doi:10.1681/ASN.2007060688
   PubMed Web of Science ®Google Scholar
• Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol. 2011;6:2499–2507. doi:10.2215/CJN.03530411
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–2418. doi:10.1056/NEJMoa1205511
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930–1942. doi:10.1056/NEJMoa1710030
   PubMed Web of Science ®Google Scholar
• Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5:693–697. doi:10.2215/CJN.04180609
   PubMed Web of Science ®Google Scholar
• Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4:1140–1150. doi:10.2215/CJN.00790209
   PubMed Web of Science ®Google Scholar
• Messchendorp AL, Casteleijn NF, Meijer E, Gansevoort RT. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2020;35:1306–1316. doi:10.1093/ndt/gfz054
   PubMed Web of Science ®Google Scholar
• Meijer E, Visser FW, van Aerts RMM, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA. 2018;320:2010–2019. doi:10.1001/jama.2018.15870
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68:206–216. doi:10.1111/j.1523-1755.2005.00395.x
   PubMed Web of Science ®Google Scholar
• Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol. 2010;5:783–789. doi:10.2215/CJN.05380709
   PubMed Web of Science ®Google Scholar
• Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21:1052–1061. doi:10.1681/ASN.2009121291
   PubMed Web of Science ®Google Scholar
• Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012;27:3532–3539. doi:10.1093/ndt/gfs152
   PubMed Web of Science ®Google Scholar
• Chrispijn M, Nevens F, Gevers TJG, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther. 2012;35:266–274. doi:10.1111/j.1365-2036.2011.04923.x
   PubMed Web of Science ®Google Scholar
• Hogan MC, Chamberlin JA, Vaughan LE, et al. Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial. Clin J Am Soc Nephrol. 2020;15:1267–1278. doi:10.2215/CJN.13661119
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010;21:489–497. doi:10.1681/ASN.2009040421
   PubMed Web of Science ®Google Scholar
• Wu M, Wahl PR, Le Hir M, et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res. 2007;30:253–259. doi:10.1159/000104818
   PubMed Web of Science ®Google Scholar
• Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010;78:754–761. doi:10.1038/ki.2010.250
   PubMed Web of Science ®Google Scholar
• Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820–829. doi:10.1056/NEJMoa0907419
   PubMed Web of Science ®Google Scholar
• Gattone VH 2nd, Cowley BD, Barash BD, et al. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis. 1995;25:302–313. doi:10.1016/0272-6386(95)90013-6
   PubMed Web of Science ®Google Scholar
• Gile RD, Cowley BD, Gattone VH, et al. Effect of lovastatin on the development of polycystic kidney disease in the Han: SPRDrat. Am J Kidney Dis. 1995;26:501–507. doi:10.1016/0272-6386(95)90497-2
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr., Hamahira K, Sweeney J, et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003;64:1310–1319. doi:10.1046/j.1523-1755.2003.00232.x
   PubMed Web of Science ®Google Scholar
• Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 2002;11:1731–1742. doi:10.1093/hmg/11.15.1731
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature. 2006;444:949–952. doi:10.1038/nature05348
   PubMed Web of Science ®Google Scholar
• Fujiki T, Ando F, Murakami K, et al. Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. Sci Rep. 2019;9:9245. doi:10.1038/s41598-019-45539-8
   PubMed Web of Science ®Google Scholar
• Omori S, Hida M, Fujita H, et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol. 2006;17:1604–1614. doi:10.1681/ASN.2004090800
   PubMed Web of Science ®Google Scholar
• Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9:889–896. doi:10.2215/CJN.08350813
   PubMed Web of Science ®Google Scholar
• Tesar V, Ciechanowski K, Pei Y, et al. Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2017;28:3404–3413. doi:10.1681/ASN.2016111232
   PubMed Web of Science ®Google Scholar
• Grantham JJ, Uchic M, Cragoe EJ, et al. Chemical modification of cell proliferation and fluid secretion in renal cysts. Kidney Int. 1989;35:1379–1389. doi:10.1038/ki.1989.137
   PubMed Web of Science ®Google Scholar
• Gardner KD Jr., Burnside JS, Skipper BJ, et al. On the probability that kidneys are different in autosomal dominant polycystic disease. Kidney Int. 1992;42:1199–1206. doi:10.1038/ki.1992.405
   PubMed Web of Science ®Google Scholar
• Belibi FA, Wallace DP, Yamaguchi T, et al. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13:2723–2729. doi:10.1097/01.asn.0000025282.48298.7b
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S90–S102. doi:10.2337/dc19-S009
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585. doi:10.1007/s00125-017-4342-z
   PubMed Web of Science ®Google Scholar
• Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002;51:2420–2425. doi:10.2337/diabetes.51.8.2420
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174. doi:10.1172/JCI13505
   PubMed Web of Science ®Google Scholar
• Rowe I, Chiaravalli M, Mannella V, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013;19:488–493. doi:10.1038/nm.3092
   PubMed Web of Science ®Google Scholar
• Lian X, Wu X, Li Z, et al. The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br J Pharmacol. 2019;176:711–724. doi:10.1111/bph.14558
   PubMed Web of Science ®Google Scholar
• Capuano I, Riccio E, Caccavallo S, De Simone I, Pisani A. ADPKD and metformin: from bench to bedside. Clin Exp Nephrol. 2019;23:1341–1342. doi:10.1007/s10157-019-01770-1
   PubMed Web of Science ®Google Scholar
• Coppolino G, Bolignano D, Rivoli L, et al. Tumour markers and kidney function: a systematic review. Biomed Res Int. 2014;2014:647541. doi:10.1155/2014/647541
   PubMed Web of Science ®Google Scholar
• Coppolino G, Leporini C, Rivoli L, et al. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacol Res. 2018;129:274–294. doi:10.1016/j.phrs.2017.12.001
   PubMed Web of Science ®Google Scholar
• Pisani A, Riccio E, Bruzzese D, Sabbatini M. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? BMC Nephrol. 2018;19:282. doi:10.1186/s12882-018-1090-3
   PubMed Web of Science ®Google Scholar
• Sorohan BM, Ismail G, Andronesi A, et al. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2019;20:276. doi:10.1186/s12882-019-1463-2
   PubMed Web of Science ®Google Scholar